Latest Breaking News On - Prostate specific membrane antigen targeted - Page 1 : comparemela.com

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMike beyerBruce spottiswoodeScintomics gmbDavid gaudenClare gidleyPriscilla harlanSiemens healthineersA siemens healthineers companyTechnical university of munichBracco groupSam brown incNuclear medicineBlue earth diagnostics ltdSolutions inc

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development

Blue Earth Diagnostics Announces Agreement with Siemens Healthineers to Share PET Imaging Agent POSLUMA® (Flotufolastat F 18) Clinical Data to Support AI-based Algorithms Development
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSiemens healthineersScintomics gmbDavid gaudenBruce spottiswoodeTechnical university of munichBracco groupBlue earth diagnostics ltdSolutions incClinical applications researchNuclear medicineA siemens healthineers companyDrug administrationClinical data to support algorithms developmentEarth diagnostics announces agreementClinical data

Blue Earth Therapeutics Announces Promising Results from Preclinical Evaluation of Synergistic Drug Combinations with Radiopharmaceutical 177Lu-rhPSMA-10 1 for Treatment of Prostate Cancer

177Lutetium-labeled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is in development as a highly optimized, next generation therapeutic radiopharmaceutical

United statesSan diegoDavide gaudenScintomics gmbTechnical university of munichAmerican association for cancer researchBlue earth therapeuticsAmerican associationCancer researchAnnual meetingProstate specific membrane antigen targetedBlue earth therapeuticChief executive officerBlue earthRadiohybrid prostate specific membrane antigenTechnical university

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10 1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1

United statesConstantin lapaDavid gaudenDepartment of nuclear medicineUniversity hospital augsburgJournal of nuclear medicineDrug administrationUniversity hospitalBlue earth therapeuticsEfficacy dataMetastatic prostate cancerNuclear medicineProstate specific membrane antigen targetedBlue earth therapeuticTherapeutic indexChief executive officer

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 1

– First reported clinical results from independent clinical experience by University of Augsburg demonstrated encouraging preliminary data for 177Lu-rhPSMA-10.1 –– 177Lutetium-labeled radiohybrid (rh) Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is now in clinical development as a highly optimized, next ge.

United kingdomUnited statesMike beyerPriscilla harlanDavid gaudenClare gidleyConstantin lapaUniversity hospital augsburgCorporate communicationsUniversity hospitalUniversity of augsburgDepartment of nuclear medicineBracco groupJournal of nuclear medicineDrug administrationSam brown inc